Blogs, Genomics

Genetic Test Catalog Management: A Clinical Control System for Assay Versions, Consent, LOINC, and Report Logic

Organized, labeled sample tubes in a clinical laboratory

Most laboratories have a test catalog. Fewer have a controlled definition of a laboratory service.

Those are not the same thing.

A catalog is often treated as a menu: test names, local codes, specimen types, prices, and ordering notes. That approach breaks down in clinical genomics and molecular diagnostics. A hereditary cancer panel, pharmacogenomics assay, carrier screen, exome, or rare-disease test is not simply an item a clinician selects. It is a set of connected commitments about what the laboratory will accept, perform, interpret, report, and deliver.

The operating question is not whether every detail sits in one application. It is whether the laboratory can show, for any accessioned case, that the service ordered, the service performed, and the report issued were governed by one coherent and approved definition.

That is the real purpose of genetic test catalog management.

Genetic Test Catalog Management Is More Than a Laboratory Test Menu

A laboratory test menu answers a basic question: What tests do we offer?

A clinical control system answers harder ones:

  1. What exactly did the clinician order?
  2. Which version of the genetic test was applied to this patient and case?
  3. Was the specimen acceptable for that assay version?
  4. Which genetic test consent, provider attestation, or supporting documentation rule applied?
  5. Which local test code, LOINC mapping, and interface rule identified the service?
  6. Which analysis configuration was authorized?
  7. Which report template, methodology, and limitations were applied?
  8. Can the laboratory reconstruct those decisions after the report is delivered?

The difference matters because a laboratory does not deliver a test name. It delivers a clinical service under defined conditions.

The Clinical Laboratory Improvement Amendments, or CLIA, require laboratories performing nonwaived testing to establish and maintain written policies and procedures for quality systems across preanalytic, analytic, postanalytic, and general laboratory activities. CMS guidance also states that laboratories need adequate manual or electronic systems to ensure results and patient-specific data are accurately and reliably sent from data entry to the final report destination. CMS CLIA interpretive guidance describes these expectations for laboratory quality systems, result transmission, and reporting.

A spreadsheet can document a test name. It does not, by itself, control the relationships that determine whether the laboratory can reliably receive, perform, report, and deliver that service.

Connect the rules that govern complex diagnostic workflows.

NonStop engineers connected clinical genomics systems that link test definition, intake, laboratory operations, analysis, reporting, integration, and downstream action.

A Genetic Test Catalog Connects Seven Clinical and Operational Commitments

No single team owns every condition attached to a clinical test. Genetic test catalog management therefore needs cross-functional ownership and controlled relationships among the records that define the service.

CommitmentWhat the catalog must defineFailure when disconnected
ClinicalIntended use, indication, eligibility, ordering guidance, exclusionsThe wrong test is ordered or the laboratory accepts a case outside approved policy
ConsentRequired consent, attestation, disclosure, documentation, review triggers, exception pathIntake accepts incomplete or mismatched documentation, or staff rely on manual memory
AnalyticalAssay version, gene content, variant classes, reportable range, methodology, limitationsThe laboratory cannot establish which analytical service applied to a case
OperationalSpecimen type, collection instructions, transport, rejection rules, turnaround, reflex rulesPreventable preanalytic exceptions enter downstream workflow
InformaticLocal code, provider-facing name, LOINC, EHR mapping, accessioning identifiers, interface behaviorExternal orders map incorrectly or duplicate services become indistinguishable
ReportingReport template, result categories, methodology, limitations, structured fields, sign-out eligibilityReport language does not match the assay performed
CommercialCPT, diagnosis-code dependencies, payer workflows, authorization and financial-policy rulesBilling and authorization work becomes detached from the clinical service definition

Genetic testing adds dependencies that ordinary catalog models often miss: genes and transcripts, reportable ranges, family-history requirements, secondary-finding policies, reanalysis rules, and sensitive information with implications for relatives.

CDC guidance for molecular genetic testing notes that laboratories need enough patient and test-request information to perform testing and report results accurately. It also distinguishes CLIA from broader consent responsibilities: CLIA itself does not require laboratories to document informed consent for requested tests, while state or local requirements, institutional policies, provider responsibilities, and test-specific considerations may apply. CDC guidance for molecular genetic testing provides that context.

A catalog should not merely store a link to a consent form. It should support an operational determination: Does the documentation satisfy the approved rule for this patient, this test, and this service version?

The outcome may be an automated pass, a hold, an exception queue, or qualified human review. The policy remains a clinical, laboratory, compliance and legal responsibility. Engineering makes the approved policy explicit, traceable, and operational.

Assay Version Management Requires More Than a Genetic Test Name

A test name is valuable for human communication. It is a poor control object.

“Comprehensive Cardiomyopathy Panel” does not identify the active assay version, genes, transcript policy, variant classes, reportable range, accepted specimen types, consent rules, payer dependencies, pipeline configuration, report template, or transition policy after an assay update.

The useful catalog object is a versioned clinical service definition. It needs a stable identifier, status, effective period, approved version, named owners, change history, and controlled links to dependent records.

The display name is one attribute. It is not the definition.

LOINC, CPT, ICD-10-CM, and Local Genetic Test Codes Must Resolve to One Service

Laboratories commonly maintain several identifiers for the same test:

  • A local laboratory order code.
  • A provider-facing orderable in an EHR or portal.
  • A client-specific mapping.
  • A LOINC code or mapping where appropriate.
  • CPT mapping for procedure coding.
  • ICD-10-CM guidance or payer dependencies.
  • A reportable-result identifier.

LOINC supports standardized representation of laboratory observations and orders. ULOC is a common-orders subset, not a comprehensive catalog of laboratory-specific NGS panels. A large or laboratory-specific NGS panel may not have an exact matching LOINC order code. The laboratory should retain its local test code and approved service version, with a mapped LOINC code where an appropriate term exists. LOINC’s guidance on genetic testing and panels provides the relevant context; a LOINC mapping alone does not identify the laboratory’s complete assay scope or version.

For catalog exchange, HL7 v2 Master File Notification (MFN) messages with OM1 segments can communicate service/test master data between systems that support the agreed interface. HL7’s master-files specification describes this mechanism. MFN/OM1 exchange is distinct from placing a patient order and does not, by itself, establish a complete assay-version or clinical-policy model.

The NIH Genetic Testing Registry (GTR) provides submitted descriptions of genetic tests, methods, laboratory details, and ordering information. A GTR accession identifies a registry record, not the local order code or the laboratory’s approved assay version. It is a supporting reference, not the operational catalog or an NIH endorsement of the test.

Reduce ambiguity at the order boundary.

SmartReq supports structured requisition intake, required-field validation, consent-aware exceptions, and workflow decisions before incomplete or mismatched cases move downstream.

Assay Version Management: Release a Genetic Test Version Bundle

An assay change is rarely only an assay change. It may alter reportable content, limitations, documentation requirements, codes, pipeline settings, report language, or delivery rules.

The relevant control unit is a version bundle: the group of dependent records that must be reviewed together when a service changes.

Version-controlled artifactWhy it belongs in the bundle
Clinical service definitionEstablishes the orderable service and intended use
Assay definitionEstablishes analytical method and scope
Gene, region, transcript, and variant-class scopeDefines evaluated and reportable content
Specimen and intake rulesDetermines whether the laboratory may accept and process the case
Consent and documentation policyDetermines whether required documentation is present or requires review
Local code, LOINC, and client-order mappingsDetermines how external systems identify the service
CPT and payer configurationDetermines commercial workflow interpretation
Pipeline and annotation configurationDetermines how analysis runs in production
Report specificationDefines methodology, limitations, structured results, and narrative output
Delivery rulesDetermines how results reach EHRs, portals, and providers
Effective dates and transition policyDetermines which version governs an order, accession, report, amendment, or reanalysis

A version bundle does not require a monolithic platform. It requires traceable relationships. A catalog may retain an approved assay identifier, a LIMS may retain workflow configuration, a pipeline platform may retain a release tag, a reporting system may retain a template version, and an interface engine may retain mapping revisions. The laboratory must be able to show that active components resolve to an approved service version.

Effective Dates and Genetic Test Version Transitions Need Defined Rules

Version boundaries create the most difficult cases:

  • An order arrives before a new assay becomes effective but is accessioned after the release.
  • A sample is accessioned before the release but analyzed after it.
  • A failed case requires rework after a new version becomes active.
  • A report is drafted using a previous template after a new assay is released.
  • A historical case is amended or reanalyzed under current knowledge.

The laboratory should define whether the governing date is the order date, accession date, analytical-start date, final-report date, a manual release decision, or a controlled combination. The correct policy depends on laboratory-specific clinical and quality decisions. The system should make that decision visible and preserve it.

LIMS Test Catalog Management Needs a Connected Control Model

Each platform holds a valid but incomplete view of the service.

SystemCommon strengthWhat it rarely governs alone
EHRProvider-facing orderables and clinical contextAssay versions, laboratory specimen rules, pipeline releases, report eligibility
LISOrder receipt, accessioning, results, laboratory operationsFull consent policy, external mappings, payer dependencies, bioinformatics release controls
LIMSSample tracking, wet-lab workflow, instruments, QCProvider order experience, consent policy, billing, EHR result mapping
Bioinformatics platformAnalysis execution, annotation, QC, traceabilityOrder eligibility, documentation rules, payer policy, result delivery
Reporting systemReport assembly, templates, sign-outWhether report content matches the ordered and performed service
Revenue-cycle systemClaims, coding, authorization, denialsAssay scope, report correctness, specimen acceptance
Spreadsheet or document repositoryReference informationReal-time validation, cross-system enforcement, release control

The question is not which system should own every catalog field. The question is which system is the canonical source of the controlled clinical service definition, and how other systems receive, validate, or reconcile the information they need.

Clinical Laboratory Test Catalog Architecture: One Canonical Definition, Many Views

A practical target architecture has one canonical definition and several controlled system views:

Versioned clinical service definition
  • Provider portal and EHR orderable view
  • SmartReq intake, documentation, and exception rules
  • LIS and LIMS accessioning and specimen rules
  • Intergenix HL7 v2 and FHIR order-mapping rules
  • Bioinformatics workflow and pipeline-release rules
  • Clinical review requirements
  • ReportStudio report eligibility and template rules
  • Billing, authorization, and payer mappings
  • EHR result delivery and structured-result mappings
  • Audit, approval, release, amendment, and historical records

The model needs to resolve the active service definition at order receipt, validate required conditions early, lock the applicable configuration at an approved workflow point, prevent report-template drift, and preserve historical context when a service evolves.

CMS guidance states that laboratory reports should be legible, understandable, and complete, and that systems should support accurate and reliable transmission of patient-specific data to the final report destination. CMS CLIA interpretive guidance addresses report content and result transmission.

A scanned form, portal confirmation, or attached PDF is consent capture. Consent validation asks whether the documentation meets the active rule for the particular service and patient context.

Depending on laboratory policy and applicable requirements, that evaluation may consider form version, signatures, dates, patient identity, test linkage, provider attestation, jurisdictional requirements, clinical versus research distinction, secondary-finding preferences, and review exceptions.

Consent to undergo a genetic test and HIPAA privacy requirements answer different questions. Testing consent concerns whether the patient agreed to the test under applicable law and clinical policy. HIPAA governs the privacy and permitted use or disclosure of protected health information; it does not, by itself, establish informed consent to perform genetic testing.

HHS OCR guidance confirms that individually identifiable genetic information can be PHI when it meets the HIPAA definition. HHS also distinguishes privacy consent from HIPAA authorization. The catalog should therefore track testing-consent requirements separately from any applicable PHI-use or disclosure requirements. A HIPAA authorization is not a substitute for required testing consent, and testing consent does not replace any separate authorization required for a particular use or disclosure.

Connect external orders to laboratory rules and exception workflows.

Intergenix engineers validated HL7 v2 and FHIR order, status, and result workflows so laboratories can reconcile external clinical requests with controlled internal service definitions.

Genetic Test Catalog Governance Requires Named Owners

A data model does not create accountability. Catalog control requires a release model with named authority.

Decision areaAccountable ownerRequired contributors
Intended use, eligibility, reportabilityMedical director or designated clinical leaderGenetic counseling, clinical operations, laboratory leadership
Assay scope, methodology, reportable range, limitationsLaboratory directorMolecular operations, bioinformatics, quality
Specimen and preanalytic requirementsLaboratory operations leaderAccessioning, quality, client services
Consent and documentation rulesCompliance and clinical leadershipLegal counsel, genetic counseling, laboratory operations
Orderables, LOINC, local codes, interface mappingsLaboratory informatics leaderIntegration engineering, client implementation, operations
Pipeline release configurationBioinformatics leaderLaboratory director, quality, platform engineering
Report templates and sign-out rulesMedical director or reporting leaderReporting operations, laboratory quality
CPT, payer, authorization, and order-to-cash mappingRevenue-cycle leaderClient services, compliance, finance
Release approval and effective-date policyNamed change-control authorityAll affected owners

This model establishes who can approve a revised gene list, change a limitation statement, activate an EHR orderable, update consent requirements, alter a report template, or retire an older service version.

CMS guidance on verification of performance specifications states that laboratories must verify applicable performance characteristics before reporting patient results when an unmodified FDA-cleared or approved nonwaived test system is introduced under the specified circumstances. CMS verification guidance explains these requirements. Qualified laboratory leadership must determine the validation, verification, quality, and change-control obligations that apply to a specific test-system change.

Four Controls for a Defensible Genetic Test Catalog

A laboratory can assess genetic test catalog management before selecting new software.

1. Reconstruct the Clinical Service for Every Completed Case

For any completed patient case, can the laboratory identify the ordered service, active catalog version, applicable documentation rule, assay and pipeline configuration, report specification, delivery route, approvals and exceptions?

If the answer depends on staff memory, shared inboxes, or disconnected spreadsheets, the catalog is not a reliable clinical control system.

2. Confirm Genetic Test Order, Assay, and Report Consistency

Do the order, consent record, specimen rule, assay, pipeline, and report resolve to a compatible service version?

The control should detect mismatches before sign-out rather than after provider inquiry, patient complaint, billing exception, or report amendment.

3. Test the Assay Version Release Process

Can a laboratory publish a new service version through a defined process that identifies impacted records, validates changes, captures approvals, sets effective dates, and monitors post-release exceptions?

A release is incomplete when the new assay is live, but the EHR orderable, consent rule, pipeline, report template, payer mapping, or result interface still uses the prior definition.

4. Route Genetic Test Catalog Exceptions Early

Can the system identify and route orders that do not fit an active rule?

Examples include an older consent form, an invalid specimen type, an external code with no active mapping, a payer condition needing review, a mismatched report template, or a case requiring a transition-policy decision. A mature workflow detects these cases early, assigns ownership, and records resolution.

What NonStop Engineers Around the Catalog

A governed genetic test catalog platform provides a foundation for connecting approved service definitions with ordering, intake, analysis, reporting, and delivery.

NonStop builds and integrates the software, data model, workflow controls, and interfaces needed to make that platform work across the laboratory’s systems. Release procedures, named ownership, and an audit trail keep the service definition controlled as tests change.

  • SmartReq supports structured requisition and intake workflows, including extraction, required-field validation, consent-aware exception handling, and routing of incomplete orders.
  • Intergenix connects EHR, LIS, LIMS, portal, and downstream workflows through HL7 v2 and FHIR mappings, validation, reconciliation, and exception management.
  • Custom LIMS and laboratory workflow engineering support accessioning, specimen tracking, wet-lab routing, QC gates, instrument workflow, and case-state controls tied to the approved service definition.
  • Bioinformatics workflow engineering connects assay releases to production pipeline configuration, monitoring, re-run controls, and traceability.
  • ReportStudio and clinical reporting engineering connect the performed service to approved report content, structured results, sign-out workflow, amendments and result delivery.
  • Forward-deployed engineering gives laboratory teams an embedded technical partner to map the current state, establish the control model, integrate the required systems, and transfer durable ownership to the organization.

The result should not be another disconnected catalog interface.

It should be a traceable chain from orderable service to final clinical report.

Start Your Genetic Test Catalog Management Review With Three Complex Tests

Choose three tests:

  1. A high-volume panel that has changed gene content, methodology or reportable range.
  2. A test with complex consent, clinical history, or genetic counselling requirements.
  3. A service with multiple payer, EHR, client, or report-delivery pathways.

For each service, collect the provider-facing orderable, assay definition, consent rule, LOINC and local mappings, specimen requirements, pipeline configuration, report template, payer dependencies, delivery setup, and historical version policy.

Then ask one question:

Can every one of these records be tied to one approved, versioned clinical service definition?

If not, the laboratory has a catalog-control gap.

Assess the Controls Behind Your Genetic Test Catalog

NonStop’s Architecture Review maps whether test definitions, assay versions, consent rules, LOINC and local order mappings, laboratory workflow, pipeline releases, report templates, and result delivery are governed as one traceable clinical service.

Genetic Test Catalog Management FAQs

What is genetic test catalog management?

Genetic test catalog management is the governance of the clinical services a laboratory offers. It connects the test orderable, assay version, consent rules, specimen criteria, coding, workflow configuration, report logic, delivery requirements, and historical record for each service.

Why does a genetic test catalog need assay version control?

Assay version control records the analytical definition that applied to a case, including relevant methodology, gene content, reportable range, variant classes, limitations, and workflow configuration. Without it, a laboratory may not be able to reconstruct the service performed or determine whether a report describes the correct assay.

Does CLIA require consent for genetic testing?

CLIA does not generally require laboratories to document informed consent for requested tests. State requirements, institutional policies, provider responsibilities, test-specific considerations, and other applicable requirements may create consent obligations. Qualified clinical, laboratory, compliance, and legal stakeholders should determine the policy that applies. CDC guidance for molecular genetic testing discusses this distinction.

Is a LIMS enough for genetic test catalog management?

A LIMS can be central to test setup, sample tracking, wet-lab workflow, and quality-control operations. It may not govern provider-facing orderables, consent requirements, EHR mappings, payer dependencies, pipeline releases, report templates, and result-delivery rules. The essential requirement is a controlled and traceable definition that links relevant systems.